Neuron Bio reaches agreement with Centro de Diagnóstico to market its non-invasive diagnostic test for Alzheimer’s disease

Neuron Bio has signed an agreement with Centro de Diagnóstico for marketing its non-invasive diagnostic test for Alzheimer’s disease, which is carried out through a blood test.

The diagnostic test, which is based on a method protected by European patent application, is carried out by analyzing biomarkers in blood. Thus, it allows the specialist in neurological diseases to have an additional tool to help in the diagnosis of patients at risk for Alzheimer’s disease in a reliable, easy and non-invasive way.

Neuron Bio will make available to Centro de Diagnóstico its technology and know-how developed in the area of ​​diagnosis in recent years, while Centro de Diagnóstico will provide its technical department and knowledge acquired in the field of clinical diagnosis. Jointly, commercial exploitation of the diagnostic test will be possible. Soon, both companies will give more detailed information on the practical application, the procedures and the start of tests.

The agreement for commercialization of the diagnostic test for Alzheimer’s disease is part of the new company strategy, thought to focus its resources in this area on its tenth anniversary. This first initiative will continue with a round of presentations related to the developed technologies and clinical studies already carried out, to a network of specialized physicians in this neurodegenerative disease.

In words of Javier Burgos, the CEO of Neuron Bio, “In 2016, this partnership will allow testing 1,500 individuals at risk for Alzheimer’s disease, if we get a good market penetration. To this end, Neuron already offers its patented technology to patients suspected of suffering Alzheimer’s disease through medical specialists, who have at their disposal extraction points next to their consultations that will forward to Centro de Diagnóstico the necessary blood samples for conducting the diagnostic tests. We begin the new business plan of the company with great momentum thanks to this agreement. “

Alberto Machado, managing director of Centro de Diagnóstico said, “This agreement allows our centers to work with a new state-of-the-art diagnostic test, within the personalized medicine in the field of neurology, and focused on a disease with increasing incidence in society. We are very pleased that Neuron has trusted us for it.”